New and Emerging Immunotherapy Combos for Advanced RCC: Finding the Right Treatments

Christina T. Loguidice
Published: Friday, Aug 16, 2019
Sumanta Kumar Pal, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, and codirector, Kidney Cancer Program, City of Hope

Sumanta Kumar Pal, MD

Emerging immunotherapy combinations have offered a strong challenge to sunitinib (Sutent) in the setting of frontline advanced clear cell renal cell carcinoma (RCC). For oncologists, the challenge now is to determine which of these combinations will produce optimal results in the setting of intermediate and high-risk disease, according to a panel of experts who discussed the issue in a recent OncLive Peer Exchange®. In addition, there still appears to be a role for sunitinib among favorable-risk patients. This may be because sunitinib’s role as an angiogenesis inhibitor at this stage in disease progression is more dominant, the panel speculated.

Table 1. Efficacy Data From Phase III Trials Leading to FDA Approval of Checkpoint Inhibitor Combinations in Metastatic RCC

Table 1. Efficacy Data From Phase III Trials Leading to FDA Approval of Checkpoint Inhibitor Combinations in Metastatic RCC

, said. “In our clinics, we use IMDC [International Metastatic Renal Cell Carcinoma Database Consortium] risk criteria to risk stratify our patients and get a sense of who has favorable-risk disease versus intermediate- or poor-risk disease with more guarded prognoses.”

Table 2. FDA Indications and NCCN Recommendations on Use of FDA-Approved Immunotherapy Combinations for Clear Cell Metastatic RCC

Table 2. FDA Indications and NCCN Recommendations on Use of FDA-Approved Immunotherapy Combinations for Clear Cell Metastatic RCC
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x